Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer’s disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect’s pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates (ADCs). ?Intellect’s?flagship?CONJUMAB platform empowers monoclonal antibodies targeting amyloidogenic proteins with additional neuroprotective properties by combining them chemically with a small molecule such as an antioxidant.
The company’s ADC- based technology has the potential to improve on current methods of passive immunotherapy by increasing clearance of amyloid proteins while delivering potent cytoprotective molecules to sites of damage in the brain and other organs.? CONJUMAB-A,?the first compound from this platform, is designed to reduce inflammation caused by amyloidosis while avoiding vasogenic edema, a side effect of plaque dissolution that occurs in some patients.
The company?s lead CONJUMAB-A candidate is IN-N01-OX2, a non-activating, stabilized IgG4 humanized antibody specific for beta amyloid protein conjugated to melatonin, which is a naturally occurring molecule with potent anti-oxidant and anti-fibrillogenic properties.
Beta amyloid, when it accumulates in the retina of the eye, causes damage by oxidative stress. The conjugate is anticipated to increase the therapeutic window for melatonin to protect retinal epithelial cells, promote clearance of beta-amyloid away from sites of damage and limit potential off-target side-effects.
CONJUMAB-A may also have potential applications for diabetic retinopathy, glaucoma, traumatic brain injury, and Alzheimer’s disease.
45 West 36th Street, 3rd Floor
New York, NY 10018
Web: Intellect Neurosciences Inc.
